Flushing and gastrointestinal adverse event analysis from the phase 3 EVOLVE-MS-1 study of diroximel fumarate in patients with relapsing-remitting multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2022
This article has no abstract
Epistemonikos ID: 52f829616cfa15bed6dcbf51993598c949409786
First added on: Apr 30, 2026